Didier Neau
Hôpital Pellegrin, 33076 Bordeaux Cedex, France
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Didier Neau as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 00:31 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT00221650 · Treatment of Chronic Hepatitis C With PEG Interferon alfa2a and Ribavirin in HIV-infected PatientsUniversity Hospital, Bordeaux · completed · HIV Infections, Hepatitis C, Chronic, Treatment Failure · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 00:31 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 00:31 UTC. The ranking covers the 200 most relevant of 17 PubMed records, and a shared surname and initials can bring in a namesake. All 17 on PubMed
- Human immunodeficiency virus type 1 genotypic and pharmacokinetic determinants of the virological response to lopinavir-ritonavir-containing therapy in protease inhibitor-experienced patients.Antimicrob Agents Chemother · 200298 citationsRCR 2.3
- 78 citationsRCR 1.9
- 58 citationsRCR 1.5
- Virological responses to atazanavir-ritonavir-based regimens: resistance-substitutions score and pharmacokinetic parameters (Reyaphar study).Antivir Ther · 200648 citationsRCR 1.4
- Long-term Immune Response to Hepatitis B Virus Vaccination Regimens in Adults With Human Immunodeficiency Virus 1: Secondary Analysis of a Randomized Clinical Trial.JAMA Intern Med · 201638 citationsRCR 1.4
- Estimation of dynamical model parameters taking into account undetectable marker values.BMC Med Res Methodol · 200636 citationsRCR 1.0
- Telaprevir for HIV/hepatitis C virus-coinfected patients failing treatment with pegylated interferon/ribavirin (ANRS HC26 TelapreVIH): an open-label, single-arm, phase 2 trial.Clin Infect Dis · 201426 citationsRCR 0.8
- Prognostic factors of combined viral load and CD4+ cell count responses under triple antiretroviral therapy, Aquitaine cohort, 1996-1998.J Acquir Immune Defic Syndr · 200125 citationsRCR 0.6
- Mechanism of virologic failure after substitution of a protease inhibitor by nevirapine in patients with suppressed plasma HIV-1 RNA.J Acquir Immune Defic Syndr · 200118 citationsRCR 0.5
- Comparison of 2 regimens that include interferon-alpha-2a plus ribavirin for treatment of chronic hepatitis C in human immunodeficiency virus-coinfected patients.Clin Infect Dis · 200314 citationsRCR 0.4